<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Red biotechnology is gaining momentum through cell and gene therapies, biopharmaceutical innovation, genetic testing, chronic disease demand, healthcare funding and pharma M&A.Dublin, Sept. 15, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- <a href="https://www.researchandmarkets.com/reports/5921382/red-biotechnology-market-size-share-forecast?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=6rwslq&amp;utm_campaign=2350128+-+Red+Biotechnology+Market+Set+for+Robust+Growth+Through+2035%2c+Fueled+by+Precision+Medicine%2c+Gene+Therapies+and+Biopharmaceutical+Innovation&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="Red Biotechnology Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)">"Red Biotechnology Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)"</a> has been added to ResearchAndMarkets.com's offering. The global red biotechnology market was valued at USD 410.54 million in 2025 and is projected to reach USD 749.20 million by 2035. The market is expected to expand at a compound annual growth rate (CAGR) of 6.20% during the 2026-2035 forecast period, driven by innovation in biopharmaceutical production, gene therapy, genetic testing and precision medicine. Rising demand for advanced treatments, growing awareness of therapies for chronic diseases and a strong pipeline of therapeutic candidates are supporting global market growth. Increased healthcare investment, continued pharmaceutical research and the expanding use of biotechnology in oncology and rare disease treatment are also strengthening the outlook for the red biotechnology industry. Latest Red Biotechnology Market News April 2026: Eli Lilly Acquires Kelonia Therapeutics Eli Lilly's acquisition of in vivo cell therapy developer Kelonia Therapeutics highlights the growing strategic importance of cell and gene therapy assets within global pharmaceutical pipelines. The transaction represented at least the sixth acquisition in the segment since March 2025 and was reported as the largest by total potential proceeds during that period. The deal followed other Eli Lilly transactions, including the acquisition of Ajax and its clinical-stage myelofibrosis therapy. This activity reflects the pharmaceutical industry's efforts to strengthen product pipelines ahead of an estimated USD 170 billion patent cliff, which is expected to intensify competition for innovative biotechnology platforms and clinical-stage therapies. March 2026: Novartis-Avidity Biosciences Transaction Moves Toward Completion Novartis's USD 12 billion acquisition of Avidity Biosciences advanced toward an anticipated closing in the first half of 2026. The transaction followed BioMarin Pharmaceutical's USD 4.8 billion agreement to acquire Amicus Therapeutics, announced on December 19, 2025. Improved clarity surrounding U.S. healthcare policy and additional interest-rate reductions have contributed to a more supportive environment for biotechnology investment and mergers and acquisitions. Industry analysts have consequently identified 2026 as a potentially significant investment period for red biotechnology, particularly across gene therapy, cell therapy and rare disease portfolios. Red Biotechnology Market Size and Forecast <ul><li>Market size in 2025: USD 410.54 million</li><li>Projected market size in 2035: USD 749.20 million</li><li>Forecast CAGR from 2026 to 2035: 6.20%</li></ul> Market Segmentation by Application <ul><li>Biopharmaceutical production</li><li>Gene therapy</li><li>Pharmacogenomics</li><li>Genetic testing</li></ul> Biopharmaceutical production remains a major application segment, supported by demand for innovative biologic medicines and targeted treatments. Gene therapy is also expected to gain momentum as clinical research advances and pharmaceutical companies increase investment in next-generation therapeutic platforms. Pharmacogenomics and genetic testing are benefiting from the wider adoption of precision medicine and more individualized treatment strategies. Market Segmentation by End Use <ul><li>Pharmaceutical industry</li><li>Contract manufacturing organizations and contract research organizations</li><li>Research institutes</li><li>Other end users</li></ul> Pharmaceutical companies represent an important source of demand due to expanding research pipelines, clinical trials and commercialization programs. Contract manufacturing and research organizations are also gaining prominence as drug developers outsource specialized development, testing and production activities. Research institutes continue to support innovation through studies focused on cancer, genetic disorders, regenerative medicine and other complex diseases. Regional Market Coverage <ul><li>North America</li><li>Europe</li><li>Asia Pacific</li><li>Latin America</li><li>Middle East and Africa</li></ul> North America and Europe remain central to red biotechnology research, financing and commercialization, supported by established pharmaceutical industries and extensive clinical development capabilities. Asia Pacific presents additional growth opportunities as healthcare expenditure rises, biotechnology infrastructure expands and regional governments promote life sciences research and domestic drug production. Market Growth Drivers The global red biotechnology market is benefiting from increasing demand for gene therapies, clinical research and advanced treatment platforms. Growing cancer prevalence is accelerating the use of biotechnology in disease research, therapeutic development and biomarker identification. Stem cell banking and regenerative medicine applications are also contributing to market expansion as awareness and access improve. At the same time, increased healthcare funding and pharmaceutical investment are enabling companies to advance new molecules through preclinical and clinical development. Strategic acquisitions, research collaborations and licensing agreements are expected to remain important competitive tools throughout the forecast period. Competitive Landscape The global red biotechnology market includes major pharmaceutical and biotechnology companies focused on product innovation, pipeline development, manufacturing capacity and strategic transactions. Key market participants include: <ul><li>Pfizer Inc. (NYSE: PFE)</li><li>Biogen Inc.</li><li>Amgen Inc.</li><li>AstraZeneca Plc.</li><li>Gilead Sciences, Inc.</li><li>F. Hoffmann-La Roche Ltd.</li><li>Merck KGaA</li><li>Bristol-Myers Squibb Company</li><li>Regeneron Pharmaceuticals Inc.</li><li>Other biotechnology and pharmaceutical companies</li></ul> Competitive assessment of the red biotechnology industry covers company capabilities, pipeline activity, capacity expansions, operational developments, mergers and acquisitions, and strategic partnerships. The market outlook also incorporates SWOT analysis and Porter's Five Forces analysis to evaluate competitive intensity, supplier and buyer dynamics, barriers to entry and the potential impact of substitute technologies. Key Topics Covered: 1 Preface 2 Report Coverage - Key Segmentation and Scope 3 Report Description 3.1 Market Definition and Outlook 3.2 Properties and Applications 3.3 Market Analysis 3.4 Key Players 4 Key Assumptions 5 Executive Summary 5.1 Overview 5.2 Key Drivers 5.3 Key Developments 5.4 Competitive Structure 5.5 Key Industrial Trends 6 Snapshot 6.1 Global 6.2 Regional 7 Opportunities and Challenges in the Market 8 Global Red Biotechnology Market Analysis 8.1 Key Industry Highlights 8.2 Global Red Biotechnology Historical Market (2019-2025) 8.3 Global Red Biotechnology Market Forecast (2026-2035) 8.4 Global Red Biotechnology Market by Application 8.4.1 Biopharmaceutical Production 8.4.1.1 Historical Trend (2019-2025) 8.4.1.2 Forecast Trend (2026-2035) 8.4.2 Gene Therapy 8.4.2.1 Historical Trend (2019-2025) 8.4.2.2 Forecast Trend (2026-2035) 8.4.3 Pharmacogenomics 8.4.3.1 Historical Trend (2019-2025) 8.4.3.2 Forecast Trend (2026-2035) 8.4.4 Genetic Testing 8.4.4.1 Historical Trend (2019-2025) 8.4.4.2 Forecast Trend (2026-2035) 8.5 Global Red Biotechnology Market by End-use 8.5.1 Pharmaceutical Industry 8.5.1.1 Historical Trend (2019-2025) 8.5.1.2 Forecast Trend (2026-2035) 8.5.2 CMO &amp; CRO 8.5.2.1 Historical Trend (2019-2025) 8.5.2.2 Forecast Trend (2026-2035) 8.5.3 Research Institutes 8.5.3.1 Historical Trend (2019-2025) 8.5.3.2 Forecast Trend (2026-2035) 8.5.4 Others 8.6 Global Red Biotechnology Market by Region 8.6.1 North America 8.6.1.1 Historical Trend (2019-2025) 8.6.1.2 Forecast Trend (2026-2035) 8.6.2 Europe 8.6.2.1 Historical Trend (2019-2025) 8.6.2.2 Forecast Trend (2026-2035) 8.6.3 Asia Pacific 8.6.3.1 Historical Trend (2019-2025) 8.6.3.2 Forecast Trend (2026-2035) 8.6.4 Latin America 8.6.4.1 Historical Trend (2019-2025) 8.6.4.2 Forecast Trend (2026-2035) 8.6.5 Middle East and Africa 8.6.5.1 Historical Trend (2019-2025) 8.6.5.2 Forecast Trend (2026-2035) 9 North America Red Biotechnology Market Analysis 9.1 United States of America 9.1.1 Historical Trend (2019-2025) 9.1.2 Forecast Trend (2026-2035) 9.2 Canada 9.2.1 Historical Trend (2019-2025) 9.2.2 Forecast Trend (2026-2035) 10 Europe Red Biotechnology Market Analysis 10.1 United Kingdom 10.1.1 Historical Trend (2019-2025) 10.1.2 Forecast Trend (2026-2035) 10.2 Germany 10.2.1 Historical Trend (2019-2025) 10.2.2 Forecast Trend (2026-2035) 10.3 France 10.3.1 Historical Trend (2019-2025) 10.3.2 Forecast Trend (2026-2035) 10.4 Italy 10.4.1 Historical Trend (2019-2025) 10.4.2 Forecast Trend (2026-2035) 10.5 Others 11 Asia Pacific Red Biotechnology Market Analysis 11.1 China 11.1.1 Historical Trend (2019-2025) 11.1.2 Forecast Trend (2026-2035) 11.2 Japan 11.2.1 Historical Trend (2019-2025) 11.2.2 Forecast Trend (2026-2035) 11.3 India 11.3.1 Historical Trend (2019-2025) 11.3.2 Forecast Trend (2026-2035) 11.4 ASEAN 11.4.1 Historical Trend (2019-2025) 11.4.2 Forecast Trend (2026-2035) 11.5 Australia 11.5.1 Historical Trend (2019-2025) 11.5.2 Forecast Trend (2026-2035) 11.6 Others 12 Latin America Red Biotechnology Market Analysis 12.1 Brazil 12.1.1 Historical Trend (2019-2025) 12.1.2 Forecast Trend (2026-2035) 12.2 Argentina 12.2.1 Historical Trend (2019-2025) 12.2.2 Forecast Trend (2026-2035) 12.3 Mexico 12.3.1 Historical Trend (2019-2025) 12.3.2 Forecast Trend (2026-2035) 12.4 Others 13 Middle East and Africa Red Biotechnology Market Analysis 13.1 Saudi Arabia 13.1.1 Historical Trend (2019-2025) 13.1.2 Forecast Trend (2026-2035) 13.2 United Arab Emirates 13.2.1 Historical Trend (2019-2025) 13.2.2 Forecast Trend (2026-2035) 13.3 Nigeria 13.3.1 Historical Trend (2019-2025) 13.3.2 Forecast Trend (2026-2035) 13.4 South Africa 13.4.1 Historical Trend (2019-2025) 13.4.2 Forecast Trend (2026-2035) 13.5 Others 14 Market Dynamics 14.1 SWOT Analysis 14.1.1 Strengths 14.1.2 Weaknesses 14.1.3 Opportunities 14.1.4 Threats 14.2 Porter's Five Forces Analysis 14.2.1 Supplier's Power 14.2.2 Buyer's Power 14.2.3 Threat of New Entrants 14.2.4 Degree of Rivalry 14.2.5 Threat of Substitutes 14.3 Key Indicators for Demand 14.4 Key Indicators for Price 15 Value Chain Analysis 16 Competitive Landscape 16.1 Market Structure 16.2 Company Profiles 16.2.1 Pfizer Inc. 16.2.1.1 Company Overview 16.2.1.2 Product Portfolio 16.2.1.3 Demographic Reach and Achievements 16.2.1.4 Certifications 16.2.2 Biogen Inc. 16.2.2.1 Company Overview 16.2.2.2 Product Portfolio 16.2.2.3 Demographic Reach and Achievements 16.2.2.4 Certifications 16.2.3 Amgen Inc. 16.2.3.1 Company Overview 16.2.3.2 Product Portfolio 16.2.3.3 Demographic Reach and Achievements 16.2.3.4 Certifications 16.2.4 Astrazeneca Plc. 16.2.4.1 Company Overview 16.2.4.2 Product Portfolio 16.2.4.3 Demographic Reach and Achievements 16.2.4.4 Certifications 16.2.5 Gilead Sciences, Inc. 16.2.5.1 Company Overview 16.2.5.2 Product Portfolio 16.2.5.3 Demographic Reach and Achievements 16.2.5.4 Certifications 16.2.6 F. Hoffmann-La Roche, Ltd. 16.2.6.1 Company Overview 16.2.6.2 Product Portfolio 16.2.6.3 Demographic Reach and Achievements 16.2.6.4 Certifications 16.2.7 Merck KGaA 16.2.7.1 Company Overview 16.2.7.2 Product Portfolio 16.2.7.3 Demographic Reach and Achievements 16.2.7.4 Certifications 16.2.8 Bristol-Myers Squibb Company 16.2.8.1 Company Overview 16.2.8.2 Product Portfolio 16.2.8.3 Demographic Reach and Achievements 16.2.8.4 Certifications 16.2.9 Regeneron Pharmaceuticals Inc. 16.2.9.1 Company Overview 16.2.9.2 Product Portfolio 16.2.9.3 Demographic Reach and Achievements 16.2.9.4 Certifications 16.2.10 Others Companies Featured <ul><li>Pfizer Inc.</li><li>Biogen Inc.</li><li>Amgen Inc.</li><li>Astrazeneca Plc.</li><li>Gilead Sciences, Inc.</li><li>F. Hoffmann-La Roche, Ltd.</li><li>Merck KGaA</li><li>Bristol-Myers Squibb Company</li><li>Regeneron Pharmaceuticals Inc.</li><li>Others</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/5921382/red-biotechnology-market-size-share-forecast?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=6rwslq&amp;utm_campaign=2350128+-+Red+Biotechnology+Market+Set+for+Robust+Growth+Through+2035%2c+Fueled+by+Precision+Medicine%2c+Gene+Therapies+and+Biopharmaceutical+Innovation&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/r37ayf</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/OTkxMzBiMjctYjdkZS00NTNiLTgxYzItZTYwMjJiMmVjNzk5LTEwMjY3MzctMjAyNi0wOS0xNS1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

Red Biotechnology Market Set for Robust Growth Through 2035, Fueled by Precision Medicine, Gene Therapies and Biopharmaceutical Innovation

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn